Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global...
Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global...
Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global Operations Leadership Team Until A New Organizational Structure Is Designed And Announced In Line With The Strategic Review
如先前所報道，Evotec宣佈管理委員會變更；首席運營官Craig Johnstone博士將於2024年12月31日正式辭職；公司表示，首席運營官職能的職責將在全球運營領導團隊內部分配，直至設計並按戰略審查宣佈新組織結構。
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024
Craig Johnstone博士將於2024年12月31日辭去首席運營官職務
Distribution of responsibilities internally
內部責任分配
HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Management Board of Evotec on 01 January 2019.
德國漢堡/ACCESSWIRE/2024年11月29日/Evotec SE（法蘭克福證券交易所：EVt，SDAX/TecDAX，TRQX：EVTd，納斯達克：EVO）今天宣佈其首席運營官Craig Johnstone博士將於2024年12月31日辭職並離開公司。Johnstone博士於2012年5月加入Evotec，擔任藥物發現與創新效率高級副總裁，並於2015年4月被任命爲Evotec（法國）SAS的總裁及現場負責人。Johnstone博士於2017年1月被任命爲全球整合藥物發現負責人，並於2019年1月1日成爲首席運營官及Evotec管理委員會成員。
